Tirzepatide
InterventionGLP-1 receptor agonists14 papers33 findingsPubChem 166567236MeSH D000098860
In human studies, tirzepatide reduces body weight, BMI, fat mass, and HbA1c, while improving lipid profiles and kidney function. In a large cohort preprint, it also lowers the risks of heart failure and all-cause mortality compared to semaglutide.
- Human trial1
- Humans6
- In silico1
Outcomes
17Body weight
downin humans8downin silico1−13%
9 studies
Body weight
downin humans8downin silico1−13%
Tirzepatide decreases body weight in humans.
Reviewin patients with moderate-to-severe psoriasis and overweight or obesity
GLP-1 receptor agonists in psoriasis management · Clinics in dermatology · 1 Oct 2026
Tirzepatide decreases body weight in humans (naive: 23% vs 10%; non-naive: 17% vs 5%).
HumansGLP-1 RA-naive or non-naive type 2 diabetes12 months
Real-world treatment patterns and cost per patient achieving treatment targets among tirzepatide and semaglutide initiators in US patients with type 2 diabetes · Journal of managed care & specialty pharmacy · 30 Sep 2026
Tirzepatide decreases body weight in humans (-17.7 ± 6.0%).
Humanslithium-treated bipolar disorder12 monthsn = 20
Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort · Human psychopharmacology · 29 Sep 2026
Tirzepatide decreases body weight in humans.
Reviewoverweight and obesity
Beyond weight loss: a narrative review of tirzepatide's impact on muscle and lean mass in people with overweight and obesity · Current medical research and opinion · 28 Sep 2026
Tirzepatide decreases body weight in silico (-6.50 kg [-8.03, -4.97]).
In silicoversus semaglutide 2.4 mg/week in adults with obesity or overweight without T2D15 mg/weekWeek 72
Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes · International journal of obesity (2005) · 28 Sep 2026
Tirzepatide decreases body weight in humans (from 95 ± 20 to 80 ± 22 kg).
Humanswith standardized low-carbohydrate diet and physical activitybody24 weeksn = 122
Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight and obesity · Journal of diabetes and its complications · 25 Sep 2026
Tirzepatide decreases body weight in humans (-12.6%).
Humanssubcutaneous12 monthsn = 1,028
Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study · Journal of the Endocrine Society · 9 Sep 2026
Tirzepatide decreases body weight in humans (15-21% weight reduction).
Review20-70 weeks
Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review · Diabetes, metabolic syndrome and obesity : targets and therapy · 2 Sep 2026
Tirzepatide decreases body weight in humans.
Reviewwhen combined with diet and physical activity52 to 72 weeks
Tirzepatide (Zepbound): Indication: For once-weekly administration for chronic weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity, in adults with an initial body mass index of: 30 kg/m2 or greater (obesity), or 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, prediabetes, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease): Reimbursement Recommendation · Canadian Agency for Drugs and Technologies in Health, Ottawa (ON) · 1 Aug 2026
HbA1c
downin humans2−16% to −1.5%
2 studies
HbA1c
downin humans2−16% to −1.5%
Tirzepatide decreases HbA1c in humans (-1.5%).
Humanstype 2 diabetes4.5 ± 1.0 mg/week24 weeksn = 88
Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study-East Shizuoka Tirzepatide (ESTATE) study · Endocrine journal · 29 Sep 2026
Tirzepatide decreases HbA1c in humans (-16.0%).
Humanssubcutaneous12 months
Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study · Journal of the Endocrine Society · 9 Sep 2026
Fat mass
downin humans2
2 studies
Fat mass
downin humans2
Tirzepatide decreases fat mass in humans.
Reviewoverweight and obesity
Beyond weight loss: a narrative review of tirzepatide's impact on muscle and lean mass in people with overweight and obesity · Current medical research and opinion · 28 Sep 2026
Tirzepatide decreases fat mass in humans.
Humanswith standardized low-carbohydrate diet and physical activity24 weeksn = 122
Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight and obesity · Journal of diabetes and its complications · 25 Sep 2026
10-year ASCVD risk
no changein humans1downin humans1−9.6% to −3.7%
1 study
10-year ASCVD risk
no changein humans1downin humans1−9.6% to −3.7%
Tirzepatide has no effect on 10-year ASCVD risk in humans (-3.7%).
Humanssubcutaneous12 monthsn = 275
Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study · Journal of the Endocrine Society · 9 Sep 2026
Tirzepatide decreases 10-year ASCVD risk in humans (-9.6%).
Humansin individuals achieving at least 10% TBWLsubcutaneous12 months
Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study · Journal of the Endocrine Society · 9 Sep 2026
Psoriasis
downin humans1
1 study
Psoriasis
downin humans1
Tirzepatide decreases psoriasis in humans.
Reviewin patients with moderate-to-severe psoriasis and overweight or obesity
GLP-1 receptor agonists in psoriasis management · Clinics in dermatology · 1 Oct 2026
Albumin
upin humans1
1 study
Albumin
upin humans1
Tirzepatide increases albumin in humans.
Humanstype 2 diabetes4.5 ± 1.0 mg/week24 weeksn = 88
Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study-East Shizuoka Tirzepatide (ESTATE) study · Endocrine journal · 29 Sep 2026
LDL cholesterol
downin humans1
1 study
LDL cholesterol
downin humans1
Tirzepatide decreases LDL cholesterol in humans.
Humanstype 2 diabetes4.5 ± 1.0 mg/week24 weeksn = 88
Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study-East Shizuoka Tirzepatide (ESTATE) study · Endocrine journal · 29 Sep 2026
Body mass index
downin humans1
1 study
Body mass index
downin humans1
Tirzepatide decreases body mass index in humans (-1.5 kg/m 2).
Humanstype 2 diabetes4.5 ± 1.0 mg/week24 weeksn = 88
Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study-East Shizuoka Tirzepatide (ESTATE) study · Endocrine journal · 29 Sep 2026
eGFR
upin humans1
1 study
eGFR
upin humans1
Tirzepatide increases eGFR in humans (+13.0 ± 12.1 mL/min/1.73 m 2).
Humanslithium-treated bipolar disorder12 monthsn = 20
Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort · Human psychopharmacology · 29 Sep 2026
Lithium
upin humans1
1 study
Lithium
upin humans1
Tirzepatide increases lithium in humans (+0.08 ± 0.17 mmol/L (p = 0.030)).
Humanslithium-treated bipolar disorder12 weeksn = 23
Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort · Human psychopharmacology · 29 Sep 2026
All 17Fewer
Lean mass
downin humans1
1 study
Lean mass
downin humans1
Tirzepatide decreases lean mass in humans (10% to 30% of total weight loss).
Reviewoverweight and obesity
Beyond weight loss: a narrative review of tirzepatide's impact on muscle and lean mass in people with overweight and obesity · Current medical research and opinion · 28 Sep 2026
Diastolic blood pressure
downin silico1
1 study
Diastolic blood pressure
downin silico1
Tirzepatide decreases diastolic blood pressure in silico (-2.40 mmHg [-3.69, -1.11]).
In silicoversus semaglutide 2.4 mg/week in adults with obesity or overweight without T2D10 mg/week
Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes · International journal of obesity (2005) · 28 Sep 2026
Lean body mass
upin silico1
1 study
Lean body mass
upin silico1
Tirzepatide increases lean body mass in silico (3.40% [0.40, 6.40]).
In silicoversus semaglutide 2.4 mg/week in adults with obesity or overweight without T2D15 mg/week
Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes · International journal of obesity (2005) · 28 Sep 2026
Body fat mass
downin silico1
1 study
Body fat mass
downin silico1
Tirzepatide decreases body fat mass in silico (-3.50% [-6.66, -0.34]).
In silicoversus semaglutide 2.4 mg/week in adults with obesity or overweight without T2D15 mg/week
Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes · International journal of obesity (2005) · 28 Sep 2026
Skeletal muscle mass
no changein humans1
1 study
Skeletal muscle mass
no changein humans1
Tirzepatide has no effect on skeletal muscle mass in humans.
Humanswith standardized low-carbohydrate diet and physical activityskeletal muscle24 weeksn = 122
Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight and obesity · Journal of diabetes and its complications · 25 Sep 2026
Body mass index
downin humans1
1 study
Body mass index
downin humans1
Tirzepatide decreases body mass index in humans (from 35 ± 6 to 29 ± 7 kg/m 2).
Humanswith standardized low-carbohydrate diet and physical activitybody24 weeksn = 122
Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight and obesity · Journal of diabetes and its complications · 25 Sep 2026
HDL cholesterol
upin humans1+11%
1 study
HDL cholesterol
upin humans1+11%
Tirzepatide increases HDL cholesterol in humans (+11.3%).
Humanssubcutaneous12 months
Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study · Journal of the Endocrine Society · 9 Sep 2026
Associations
4Heart failure
downin humans2HR 0.9
2 studies
Heart failure
downin humans2HR 0.9
Tirzepatide lowers the risk of heart failure in humans (HR 0.9, 95% CI 0.86─0.93).
Humanscompared to semaglutide in patients with obesityone-yearn = 424,269
New-Onset Heart Failure in Patients with Obesity using Tirzepatide or Semaglutide · medRxiv · 26 Sep 2026 · Preprint
Tirzepatide lowers the risk of heart failure in humans.
Reviewobesity-related HFpEF
Cardiovascular protection beyond glucose lowering: GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonism in contemporary cardiology · Frontiers in cardiovascular medicine · 16 Sep 2026
Mortality
downin humans1HR 0.8
1 study
Mortality
downin humans1HR 0.8
Tirzepatide lowers the risk of mortality in humans (HR 0.8, 95% CI 0.77─0.91).
Humanscompared to semaglutide in patients with obesityone-yearn = 424,269
New-Onset Heart Failure in Patients with Obesity using Tirzepatide or Semaglutide · medRxiv · 26 Sep 2026 · Preprint
Systolic heart failure
downin humans1HR 0.8
1 study
Systolic heart failure
downin humans1HR 0.8
Tirzepatide lowers the risk of systolic heart failure in humans (HR 0.8, 95% CI 0.79─0.92).
Humanscompared to semaglutide in patients with obesityone-yearn = 424,269
New-Onset Heart Failure in Patients with Obesity using Tirzepatide or Semaglutide · medRxiv · 26 Sep 2026 · Preprint
Type 2 diabetes
downin humans1
1 study
Type 2 diabetes
downin humans1
Tirzepatide lowers the risk of type 2 diabetes in humans.
Reviewin the prediabetes subgroup of the SURMOUNT-1 trial176 weeks
Tirzepatide (Zepbound): Indication: For once-weekly administration for chronic weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity, in adults with an initial body mass index of: 30 kg/m2 or greater (obesity), or 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, prediabetes, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease): Reimbursement Recommendation · Canadian Agency for Drugs and Technologies in Health, Ottawa (ON) · 1 Aug 2026